{"log_id": 2339308272780159404, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 0.001111, "average": 0.989073, "min": 0.824647}, "location": {"width": 851, "top": 144, "height": 44, "left": 182}, "words": "由非布司他引起的XO抑制可能会提高这些药物在血浆中的浓度,从而导致中毒。因此非"}, {"probability": {"variance": 0.000114, "average": 0.995041, "min": 0.95645}, "location": {"width": 501, "top": 188, "height": 36, "left": 184}, "words": "布司他禁用于正在接受硫唑嘌呤或巯嘌呤治疗的患者"}, {"probability": {"variance": 0.000174, "average": 0.995241, "min": 0.955686}, "location": {"width": 210, "top": 232, "height": 27, "left": 224}, "words": "2.细胞毒类化疗药物"}, {"probability": {"variance": 5e-06, "average": 0.998907, "min": 0.989879}, "location": {"width": 806, "top": 257, "height": 42, "left": 228}, "words": "未进行非布司他与细胞毒类化疗药物的相互作用研究。用细胞毒类药物化疗期间使用"}, {"probability": {"variance": 1e-05, "average": 0.99767, "min": 0.988278}, "location": {"width": 266, "top": 305, "height": 34, "left": 184}, "words": "非布司他的安全性数据未知"}, {"probability": {"variance": 0.010043, "average": 0.968464, "min": 0.636116}, "location": {"width": 254, "top": 345, "height": 27, "left": 225}, "words": "3.体内药物相互作用研究"}, {"probability": {"variance": 7e-06, "average": 0.997846, "min": 0.990741}, "location": {"width": 808, "top": 370, "height": 43, "left": 227}, "words": "基于在健康受试者体内进行的药物相互作用研究,非布司他与秋水仙碱、萘普生、吲哚"}, {"probability": {"variance": 0.005541, "average": 0.966508, "min": 0.658741}, "location": {"width": 851, "top": 407, "height": 43, "left": 185}, "words": "美辛、氢氯噻嗪、华法林、地昔帕明合用时无显著相互作用。因此,非布司他可与这些药物"}, {"probability": {"variance": 2e-06, "average": 0.998234, "min": 0.996954}, "location": {"width": 45, "top": 460, "height": 25, "left": 185}, "words": "联用"}, {"probability": {"variance": 0.001062, "average": 0.977933, "min": 0.913584}, "location": {"width": 120, "top": 494, "height": 26, "left": 190}, "words": "【药物过量』"}, {"probability": {"variance": 0.00562, "average": 0.972208, "min": 0.576063}, "location": {"width": 807, "top": 517, "height": 42, "left": 228}, "words": "对健康受试者的研究表明,在连续服用300mgd的非布司7天时未发现剂量限制性"}, {"probability": {"variance": 0.0033, "average": 0.978446, "min": 0.707194}, "location": {"width": 842, "top": 554, "height": 44, "left": 185}, "words": "毒性临床研究中尚无本品过量的报道。如病人服用本品过量应接受对症治疗以及支持疗法"}, {"probability": {"variance": 0.026887, "average": 0.903947, "min": 0.577184}, "location": {"width": 120, "top": 606, "height": 25, "left": 191}, "words": "【药理毒理"}, {"probability": {"variance": 5.4e-05, "average": 0.994213, "min": 0.981615}, "location": {"width": 90, "top": 642, "height": 25, "left": 229}, "words": "药理作用"}, {"probability": {"variance": 6e-06, "average": 0.996425, "min": 0.993909}, "location": {"width": 137, "top": 613, "height": 53, "left": 848}, "words": "医药"}, {"probability": {"variance": 0.005849, "average": 0.962404, "min": 0.696223}, "location": {"width": 812, "top": 663, "height": 47, "left": 225}, "words": "非布司他为2芳基噻唑衍生物,是一种黄嘌呤氧化酶抑制剂,通过抑制尿酸合成降低"}, {"probability": {"variance": 0.015203, "average": 0.946842, "min": 0.366517}, "location": {"width": 836, "top": 698, "height": 49, "left": 185}, "words": "血清尿酸浓度。非布司他常规治疗浓度下不会抑制其他参与嘌呤和合成与谢的酶"}, {"probability": {"variance": 1e-06, "average": 0.998965, "min": 0.997647}, "location": {"width": 70, "top": 752, "height": 26, "left": 229}, "words": "药效学"}, {"probability": {"variance": 0.014169, "average": 0.950953, "min": 0.417422}, "location": {"width": 806, "top": 775, "height": 41, "left": 229}, "words": "对尿酸和黄呤浓度的影响:健康受试者服用非布司他后,24小时平均血清尿酸浓度"}, {"probability": {"variance": 0.008957, "average": 0.955295, "min": 0.664038}, "location": {"width": 729, "top": 812, "height": 39, "left": 186}, "words": "出现剂量赖性降低,嘌呤的血清平均浓度升高。此外,尿酸的每日总排泄量"}, {"probability": {"variance": 0, "average": 0.998839, "min": 0.998397}, "location": {"width": 41, "top": 812, "height": 24, "left": 971}, "words": "同时"}, {"probability": {"variance": 0.011795, "average": 0.958698, "min": 0.502349}, "location": {"width": 849, "top": 846, "height": 42, "left": 188}, "words": "每口尿液中的黄嘌呤总排泄量增多非布司他每日给药量为40mg和80mg时,24小时平均"}, {"probability": {"variance": 0.021345, "average": 0.937356, "min": 0.39896}, "location": {"width": 329, "top": 891, "height": 35, "left": 185}, "words": "血清尿酸浓度的降低率为40%-5"}, {"probability": {"variance": 0.008552, "average": 0.978162, "min": 0.4302}, "location": {"width": 807, "top": 920, "height": 42, "left": 230}, "words": "对心脏复极化的影响:分别以健康受试者痛风患者为试验对象进行试验,通过测定"}, {"probability": {"variance": 0.008259, "average": 0.971276, "min": 0.484685}, "location": {"width": 849, "top": 958, "height": 42, "left": 188}, "words": "QTc间期评估本品对心脏复极化的影响。本品每日最高剂量达300mg,稳态时对QTc间期"}, {"probability": {"variance": 0.000373, "average": 0.983224, "min": 0.955954}, "location": {"width": 63, "top": 1011, "height": 23, "left": 191}, "words": "无影响"}, {"probability": {"variance": 1e-06, "average": 0.997861, "min": 0.996529}, "location": {"width": 88, "top": 1045, "height": 24, "left": 233}, "words": "毒理研究"}, {"probability": {"variance": 0.007346, "average": 0.956737, "min": 0.626203}, "location": {"width": 809, "top": 1068, "height": 41, "left": 231}, "words": "重复给药毒性:在12个月 Beagle犬毒性试验中,剂量为15mg/kg剂量时(约为人用剂"}, {"probability": {"variance": 0.000663, "average": 0.988899, "min": 0.843011}, "location": {"width": 849, "top": 1104, "height": 42, "left": 188}, "words": "量80mg/d时血浆暴露量的4倍)在肾脏中有黄嘌呤结晶沉淀及结石。类似的情况也出现在"}, {"probability": {"variance": 0.005413, "average": 0.97118, "min": 0.647537}, "location": {"width": 850, "top": 1140, "height": 44, "left": 190}, "words": "大鼠6个月试验中,在48mg/kg(约为人用剂量80mg/时血浆暴露量的35倍)剂量时有黄"}, {"probability": {"variance": 0.004917, "average": 0.967118, "min": 0.810399}, "location": {"width": 130, "top": 1192, "height": 26, "left": 190}, "words": "嘌呤结晶沉淀"}, {"probability": {"variance": 0.005169, "average": 0.983911, "min": 0.549506}, "location": {"width": 809, "top": 1216, "height": 40, "left": 231}, "words": "遗传毒性:非布司他在有或无代谢活化时,CHL细胞染色体畸变试验结果阳性。非布"}, {"probability": {"variance": 0.000179, "average": 0.993316, "min": 0.943785}, "location": {"width": 849, "top": 1252, "height": 41, "left": 191}, "words": "司他Ames试验、人外周血淋巴细胞染色体畸变试验、L5178Y小鼠淋巴瘤细胞染色体畸变"}, {"probability": {"variance": 0.0001, "average": 0.996288, "min": 0.937192}, "location": {"width": 837, "top": 1288, "height": 41, "left": 191}, "words": "试验、小鼠微核试验、大鼠程序外DNA合成试验、大鼠骨髓细胞微核试验结果均为阴性"}, {"probability": {"variance": 0.003127, "average": 0.980175, "min": 0.721681}, "location": {"width": 807, "top": 1326, "height": 38, "left": 233}, "words": "生殖毒性:非有司他经口给药剂量达48mg/kg/d(约为人用剂量80mg/d时血浆暴露量"}, {"probability": {"variance": 6.5e-05, "average": 0.99665, "min": 0.958873}, "location": {"width": 550, "top": 1365, "height": 37, "left": 190}, "words": "的35倍)时,对雄雌大鼠生育力和生殖行为未见明显影响"}, {"probability": {"variance": 0.005539, "average": 0.976876, "min": 0.533499}, "location": {"width": 800, "top": 1400, "height": 38, "left": 233}, "words": "妊娠大鼠与家兔器官形成期经口给予非布司他剂量达到48mg/kg(约为人用剂量80mg/"}, {"probability": {"variance": 0.00112, "average": 0.988018, "min": 0.825019}, "location": {"width": 851, "top": 1437, "height": 39, "left": 188}, "words": "时血浆暴露量40-51倍),未见致畸作用。妊娠大鼠围产期经口给予48mgkg(约为人用剂"}, {"probability": {"variance": 0.002072, "average": 0.98337, "min": 0.799651}, "location": {"width": 698, "top": 1476, "height": 39, "left": 191}, "words": "量80mg/d时血浆暴露量40-51倍),可见幼仔出生死亡率增加、体重降低"}, {"probability": {"variance": 0.003949, "average": 0.986987, "min": 0.590725}, "location": {"width": 808, "top": 1512, "height": 38, "left": 233}, "words": "致癌性:F344大鼠和B6C3F1小鼠为期两年的致癌试验中,雄性大鼠和雌性小鼠分别"}, {"probability": {"variance": 0.006236, "average": 0.962626, "min": 0.617416}, "location": {"width": 848, "top": 1549, "height": 40, "left": 191}, "words": "在削量为24mg/kg(约为人用剂量80mg/时的血浆暴露量的25倍)和18.75mg/kg(约为人"}], "language": 3}